This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Oct 1;4(5):401-4.

doi: 10.1161/CIRCINTERVENTIONS.111.964668.

Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy

Jaapjan D Snoep

PMID: 22010185
DOI: 10.1161/CIRCINTERVENTIONS.111.964668

Editorial

Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy

Jaapjan D Snoep. Circ Cardiovasc Interv. 2011.

. 2011 Oct 1;4(5):401-4.

doi: 10.1161/CIRCINTERVENTIONS.111.964668.

Author

Jaapjan D Snoep

PMID: 22010185
DOI: 10.1161/CIRCINTERVENTIONS.111.964668

No abstract available

PubMed Disclaimer

Comment on

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G. Hulot JS, et al. Circ Cardiovasc Interv. 2011 Oct 1;4(5):422-8. doi: 10.1161/CIRCINTERVENTIONS.111.963025. Epub 2011 Oct 4. Circ Cardiovasc Interv. 2011. PMID: 21972404 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information